Sign in Subscribe
Drugs

Recent Findings from Ohio State University Researchers

Strategic Insights

— 2 min read

Ohio State University researchers have made significant discoveries in cancer treatment, DNA repair, and heart failure. According to recent studies, cancer treatment with interleukin (IL)-2 therapy yields a 10% to 20% response rate in patients with metastatic melanoma or renal cell carcinoma. Additionally, DNA repair genes XPB and XPD defend cells from retroviral infection, and the V2 receptor antagonist lixivaptan may be a promising therapeutic agent for heart failure treatment.

Key Takeaways:

  • Researchers from Ohio State University detail new data in cancer, specifically the effectiveness of interleukin (IL)-2 therapy in treating metastatic melanoma and renal cell carcinoma, with a 10% to 20% response rate.
  • Interleukin-2 (IL-2) treatment produces a rapid and dose-dependent increase in P-STAT5 within normal peripheral blood mononuclear cells (PBMC), which correlates with the induction of transcript for IL-2-responsive genes CIS, Pim-1, and SOCS1.
  • The generation of P-STAT5 within immune cell subsets after therapeutic administration of IL-2 varies significantly between individuals, and activated STAT5 persists within CD4(+) and CD8(+) T lymphocytes, as well as CD56(+) NK cells, for up to 3 weeks post-IL-2 treatment.
  • The human TFIIH complex proteins XPB (ERCC3) and XPD (ERCC2) play a principal role in the degradation of retroviral cDNA, which defends cells from retroviral infection.
  • XPB and XPD mutant cell lines exhibit an increase in transduction efficiency by both HIV- and Moloney murine leukemia virus-based retroviral vectors.
  • Quantitative PCR shows an increase in total cDNA molecules, integrated provirus, and 2LTR circles in XPB and XPD mutant cells.
  • The study on the V2 receptor antagonist lixivaptan suggests that it may be a promising therapeutic agent for the treatment of heart failure, as it produces a significant and dose-related increase in urine volume in patients with mild-to-moderate heart failure.

Statistics:

  • 10% to 20% response rate in patients with metastatic melanoma or renal cell carcinoma treated with interleukin (IL)-2 therapy.
  • Correlation coefficients for the induction of STAT5-regulated genes: 0.8628 for CIS, 0.6667 for Pim-1, and 0.7828 for SOCS1.
  • Dose-dependent induction of P-STAT5 detected in PBMC for up to 18 hours following in vitro pulse stimulation with IL-2.
  • 52.2 ± 15.0% of CD4(+) T cells, 57.6 ± 25.8% of CD8(+) T cells, and 54.2 ± 27.2% of CD56(+) NK cells show P-STAT5 positivity after in vitro IL-2 treatment.
  • Increase in urine volume: 1.81 with placebo to 3.91 after the 400-mg lixivaptan dose.
  • 42 diuretic-requiring patients with mild-to-moderate heart failure participated in the study on lixivaptan.

Sources:

  • Varker et al. (2006). Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy. Clinical Cancer Research, 12(19), 5850-5858.
  • Yoder et al. (2006). The DNA repair genes XPB and XPD defend cells from retroviral infection. Proc Natl Acad Sci USA, 103(12), 4622-4627.
  • Abraham et al. (2006). Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol, 47(8), 1615-1621.

Read more